The goal of CDI is to encourage the development of intellectual property with the intent of developing downstream products or technologies that will improve patient care. Research innovation developed at CDI will lead to the development of opportunities for out-licensing and commercial partnerships. In my role as chief scientific officer, I am excited to work with top researchers in the field to develop innovative therapies to treat some of the world's most difficult diseases."ĬDI offers leading scientists and researchers an opportunity to advance their work and enable Hackensack Meridian Health and its hospitals to better serve their communities. "The Center for Discovery and Innovation is accelerating the timeline from discovery to treatment. "This is an incredible time to be in the field of science, where diseases that were once considered untreatable are now curable," said Dr. Perlin is the former executive director of the Rutgers New Jersey Medical School's Public Health Research Institute (PHRI) and former director of the Rutgers Regional Biocontainment Laboratory, one of 13 National Institutes of Health (NIH)-designated national centers for pathogen research.
He is a highly accomplished biomedical researcher and administrator, and widely recognized as a global leader in antifungal drug resistance, molecular diagnostics and drug discovery. Perlin is the founding chief scientific officer and senior vice president at CDI. "As chair of the Board of Directors, I look forward to transforming biomedical research by empowering innovation."ĭr. "The Center for Discovery and Innovation encourages critical advances in medicine by bringing together today's best and brightest to enhance patient outcomes," said Dr. Barer serves as board chair of Aevi Genomics and Centrexion Therapeutics, as well as on the Board of Directors of Contrafect as lead director.
He is also managing partner at SJ Barer Consulting and advisor to the Israel Biotech Fund. He serves as chair of the Board of Directors of Teva Pharmaceuticals. He is a biotechnology industry veteran, and the founder and former chairman, president, COO and CEO of Celgene Corporation. Barer was named chair of the Board of Directors for CDI. Perlin as chief scientific officer, CDI will continue to push the boundaries of medicine forward."ĭr. Barer as chair of the Board of Directors and Dr. Garrett, FACHE, CEO of Hackensack Meridian Health. "The Hackensack Meridian Health Center for Discovery and Innovation is bringing together the greatest minds in science and medicine to make significant breakthroughs in cancer, infectious diseases and regenerative medicine research,'' said Robert C. The CDI, housed in a newly renovated state-of-the-art facility that formerly was home to the Roche Institute of Molecular Biology, offers world-class researchers a support infrastructure and culture of discovery that promotes science innovation and translation to the clinic. These world-renowned biomedical veterans will advance the mission of the CDI, which seeks to translate current innovations in science to improve clinical outcomes for patients with cancer and other life-threatening and disabling conditions. Perlin, Ph.D., as chief scientific officer at the Hackensack Meridian Health Center for Discovery and Innovation (CDI). Barer, Ph.D., as chair of the Board of Directors and David S. The 118-unit assisted living and memory care property is being constructed on 26 acres previously owned by the Wedgewood Golf Club, and could be joined in the future by active adult apartments, independent living apartments and villas.EDISON, N.J., /PRNewswire/ - Hackensack Meridian Health, New Jersey's largest and most comprehensive and integrated health network, announced the appointments of Sol J. While ALG Senior’s portfolio is heavily concentrated in the Northeast, Meridian has maintained a nationwide footprint.Īmong the communities slated to join Meridian’s portfolio is Worthington Manor, under development in Conroe, Texas. About 40% of the portfolio remained under the Meridian banner, while about 60% of the portfolio became Affinity Living Group, which has since rebranded as ALG Senior. Meridian was founded in 2010 six years later, the company split up into two entities.
Kusserow said that Amedisys’ acquisition of Contessa Health - which provides hospital-at-home and skilled nursing-at-home services - should help further build its hospice business. “We went out about two years ago and started buying up hospices, going from the eighth-largest to the third-largest hospice and spending about $700 million to build up our presence.”
“We feel good about what we’ve done in hospice,” said Amedisys CEO Paul Kusserow.
0 kommentar(er)
